Project Grant R21HL178129
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$230K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the continued clinical development of a novel pleural and tracheal sealant. The $381,000 award to the University of Vermont will fund research to: 1) define optimal manufacturing, sterilization, and storage conditions for the sealant patch; 2) further evaluate the long-term safety and efficacy of the sealant in animal models...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,865.00 to the University of Pittsburgh to develop an optimized, minimally invasive strategy to treat ischemic cardiomyopathy (ICM). The key products and services to be delivered include: Evaluating the functional, geometric, and histopathologic effects of injecting three different thermoresponsive hydrogel formulations into an ICM...
This Project Grant award of $1,331,984.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to develop new lung quantitative ultrasound (LQUS) metrics for monitoring pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The primary awardee, North Carolina State University, will work to mitigate chest-wall effects, optimize data acquisition, and apply LQUS methods in human patients with heart failure and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and test a drug-eluting chest tube to locally manage the pain associated with its use in cardiothoracic surgeries. The $275,752 award supports two key objectives: 1) completing GMP/GLP studies on the drug release kinetics, stability, and manufacturing of the drug-releasing chest tube; and 2) evaluating the mechanical...
This Project Grant award of $759,983 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of North Carolina at Chapel Hill supports research examining the diverse responses of neutrophils during Streptococcus pneumoniae pneumonia and acute lung injury. The research aims to determine changes in neutrophil transcriptomes and the lung microenvironment during the development and resolution of S. pneumoniae-induced inflammation and...
This Project Grant award of $775,992.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through Tregs impacts their immunomodulatory and tissue...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,302,038 to the Regents of the University of Michigan to conduct research on targeting dysfunctional epithelial repair in pulmonary fibrosis. The research aims to elucidate the mediators and pathways that contribute to dysfunctional epithelial phenotypes in persistent lung fibrosis, determine the impact of hypoxia-inducible factor (HIF) signaling...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...